Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Charles Clift"'
Autor:
Kevin Outterson, Unni Gopinathan, Charles Clift, Anthony D So, Chantal M Morel, John-Arne Røttingen
Publikováno v:
PLoS Medicine, Vol 13, Iss 6, p e1002043 (2016)
Kevin Outterson and colleagues outline a model to address access, conservation, and innovation of antibiotics.
Externí odkaz:
https://doaj.org/article/daca2085b4164b299d65187e97338cc0
Autor:
Tomris Türmen, Charles Clift
Publikováno v:
Bulletin of the World Health Organization, Vol 84, Iss 5, Pp 338-338
Externí odkaz:
https://doaj.org/article/1ac48e151520481bbb95f005258e6b05
Autor:
Steven J Hoffman, Kevin Outterson, John-Arne Røttingen, Otto Cars, Charles Clift, Zain Rizvi, Fiona Rotberg, Göran Tomson, Anna Zorzet
Publikováno v:
Bulletin of the World Health Organization, Vol 93, Iss 2, Pp 66-66
Externí odkaz:
https://doaj.org/article/9d4181878c2e41fc8eff251e70e3b028
Autor:
Charles Clift, John-Arne Røttingen
Publikováno v:
BMJ (Clinical research ed.). 361
Dr Tedros’s plans to reverse the trend towards earmarked funding are important but challenging, say Charles CliftandJohn-Arne Rottingen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64abeba7d4dfc17546d4dc12f98a7671
https://pubmed.ncbi.nlm.nih.gov/29789329
https://pubmed.ncbi.nlm.nih.gov/29789329
Publikováno v:
Journal of Law, Medicine & Ethics. 43:22-26
The dangers presented by antibiotic resistance (ABR) have now established themselves as a global health security issue. From an international policy perspective, three key pillars have been established: responsible access, conservation, and innovatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94ed45ee70d0ac9f17b8baf2fa11f340
https://doi.org/10.1111/jlme.12270
https://doi.org/10.1111/jlme.12270
Autor:
Unni Gopinathan, Charles Clift, Anthony D. So, Kevin Outterson, John-Arne Røttingen, Chantal M. Morel
Publikováno v:
PLOS Medicine, Vol. 13, No 6 (2016) P. e1002043
Nature Methods
PLoS Medicine, Vol 13, Iss 6, p e1002043 (2016)
PLoS Medicine
Nature Methods
PLoS Medicine, Vol 13, Iss 6, p e1002043 (2016)
PLoS Medicine
Summary Points: The current business model for antibiotics is plagued by market failures and perverse incentives that both work against conservation efforts and provide insufficient rewards to drive the development of much-needed new treatments for r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8a711de8991724720036e5b1446eccf
https://archive-ouverte.unige.ch/unige:87647
https://archive-ouverte.unige.ch/unige:87647
Autor:
Charles Clift
Publikováno v:
Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. 5:201-208
In the last 20 or so years various kinds of exclusivity have been introduced in the US, which go beyond the basic patent protection. The most important of these is patent term restoration, but other new incentives introduced include the paediatric ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::108f717d0264212de78822ccba2fc63a
https://doi.org/10.1057/jgm.2008.6
https://doi.org/10.1057/jgm.2008.6
Autor:
Göran Tomson, Charles Clift, Kevin Outterson, Zain Rizvi, John-Arne Røttingen, Steven J. Hoffman, Anna Zorzet, Fiona Rotberg, Otto Cars
Publikováno v:
Bulletin of the World Health Organization
Antimicrobial resistance is recognized as a grave threat to global health.1,2 It already causes an estimated 700 000 deaths annually and – without effective action – is predicted to cause 10 million deaths annually by 2050.3 The World Health Orga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::516a5600f98f39de49ee3e0b267347ae
https://pubmed.ncbi.nlm.nih.gov/25883395
https://pubmed.ncbi.nlm.nih.gov/25883395